Albendazole Tablet Price 1 Tablet Manufacturing Analysis-NEWS-Dingzhou Kangquan Pharmaceutical - Professional Veterinary Medicine Manufacturer

Introduction

Albendazole is a broad-spectrum anthelmintic medication used in both human and veterinary medicine to treat a variety of parasitic worm infections. This technical guide focuses on the manufacturing, quality control, performance characteristics, and potential failure modes of albendazole tablets, specifically addressing the considerations relevant to pharmaceutical manufacturing and procurement professionals. Albendazole's efficacy stems from its inhibition of microtubule polymerization, disrupting the metabolic processes within parasitic cells. Within the pharmaceutical supply chain, ensuring consistent bioavailability, chemical purity, and physical stability are paramount concerns. This document aims to provide a comprehensive understanding of these factors, along with relevant industry standards and best practices. The focus here is on a single tablet dosage form, reflecting a common unit for clinical application and quality assessment.

Material Science & Manufacturing

The primary active pharmaceutical ingredient (API) is albendazole (methyl [5-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate), a benzimidazole derivative with a molecular weight of 265.3 g/mol. Albendazole exhibits very low aqueous solubility, presenting a significant challenge in formulation development to achieve adequate bioavailability. Excipients commonly used in albendazole tablet formulation include microcrystalline cellulose (MCC) as a diluent, sodium starch glycolate as a disintegrant, magnesium stearate as a lubricant, and possibly colloidal silicon dioxide as a glidant. MCC provides compressibility and bulk to the tablet, while sodium starch glycolate facilitates rapid tablet disintegration in the gastrointestinal tract. Magnesium stearate prevents sticking to manufacturing equipment, and colloidal silicon dioxide improves powder flow characteristics. Manufacturing typically involves wet granulation, dry granulation (slugging or roller compaction), or direct compression. Wet granulation, while offering improved content uniformity, requires careful control of granulation parameters (binder concentration, drying temperature) to prevent albendazole degradation. Direct compression is preferred for its simplicity but necessitates excipients with excellent flow and compressibility. Critical process parameters include mixing time, granulation end-point (moisture content), drying temperature, blending uniformity, and compression force. Particle size distribution of the API and excipients is meticulously controlled through milling and sieving processes to ensure consistent blending and tablet characteristics. Polymorphic forms of albendazole are also monitored, as differing crystal structures can influence solubility and bioavailability.

Performance & Engineering

The primary performance metric for albendazole tablets is bioavailability, specifically the rate and extent to which the API is absorbed into the systemic circulation. This is heavily influenced by the tablet's disintegration and dissolution characteristics. Disintegration testing, typically performed using USP apparatus 1 (basket method) or apparatus 2 (paddle method), measures the time required for the tablet to break down into smaller particles. Dissolution testing, conducted under standardized conditions (pH, agitation rate, temperature), quantifies the rate at which albendazole is released from the tablet matrix. Pharmacokinetic studies are crucial to correlate in vitro dissolution data with in vivo bioavailability. Mechanical strength (hardness, friability) is also a critical engineering parameter. Tablets must possess sufficient hardness to withstand handling during packaging and transportation without chipping or breaking. Friability testing measures the tablet's tendency to lose mass due to abrasion. Environmental resistance, specifically humidity and temperature, is evaluated through stability studies, adhering to ICH guidelines. Albendazole is susceptible to degradation under high humidity conditions, potentially forming degradation products that reduce efficacy and safety. Compliance with pharmacopeial standards (USP, EP, JP) mandates stringent control of impurities, residual solvents, and heavy metals.

Technical Specifications

Parameter	Specification	Test Method	Acceptance Criteria
Assay (Albendazole Content)	90.0% - 110.0%	HPLC	Within specified range
Related Substances (Impurities)	Individual impurity ≤ 0.1%, Total impurities ≤ 0.5%	HPLC	Meets pharmacopeial limits
Dissolution (15 minutes)	≥ 75%	USP Apparatus 2	Minimum 75% drug released
Water Content	≤ 1.0%	Karl Fischer Titration	Within specified limit
Hardness	40-80 N	Tablet Hardness Tester	Within specified range
Friability	≤ 1.0%	Friabilator	Maximum 1.0% weight loss

Failure Mode & Maintenance

Common failure modes for albendazole tablets include chipping, capping, lamination, and sticking during manufacturing, primarily stemming from inadequate lubrication, insufficient compression force, or improper excipient blending. Post-manufacturing failures include tablet disintegration failure (due to insufficient disintegrant or over-granulation), dissolution failure (related to polymorphism or poor wetting), and degradation due to exposure to humidity or light. Tablet softening can occur due to hygroscopic excipients absorbing moisture. Chemical degradation can lead to the formation of inactive or potentially toxic byproducts. Maintaining a robust quality management system (QMS) is critical. This includes regular calibration of manufacturing equipment, adherence to standard operating procedures (SOPs), comprehensive batch record review, and rigorous stability testing. Proper storage conditions (controlled temperature and humidity, protected from light) are essential to prevent degradation. Corrective and preventative actions (CAPA) should be implemented to address any identified deviations or failures. Routine monitoring of critical process parameters (CPP) and critical quality attributes (CQAs) is crucial for ensuring consistent product quality. Furthermore, supplier qualification programs are essential to verify the quality and consistency of raw materials.

Industry FAQ

Q: What are the critical considerations for scaling up albendazole tablet manufacturing from pilot to commercial scale?

A: Scale-up requires careful consideration of mixing times, blending uniformity, and heat transfer characteristics. Maintaining consistent granule size distribution and ensuring adequate lubrication become more challenging at larger scales. Process Analytical Technology (PAT) tools can be invaluable for real-time monitoring and control of critical process parameters. Computational Fluid Dynamics (CFD) modeling can help optimize mixing and granulation processes.

Q: How does the choice of excipients impact the bioavailability of albendazole?

A: Excipient selection is paramount. Disintegrants like sodium starch glycolate are vital for rapid tablet breakdown. Solubilizers or surfactants can improve the wetting of albendazole particles, enhancing dissolution. The type and amount of binder used in wet granulation affect granule hardness and disintegration. MCC grade and particle size also influence compressibility and tablet strength.

Q: What analytical methods are used to ensure the identity and purity of albendazole API?

A: High-Performance Liquid Chromatography (HPLC) with UV detection is the primary method for assay and impurity profiling. Mass spectrometry (MS) coupled with HPLC provides enhanced sensitivity and specificity for identifying degradation products. Infrared (IR) spectroscopy confirms the chemical structure. Titration can be used for quantifying the API content. Differential Scanning Calorimetry (DSC) assesses polymorphism.

Q: What are the typical stability testing conditions for albendazole tablets as per ICH guidelines?

A: Stability studies are conducted under various temperature and humidity conditions, including 25°C/60% RH (long-term), 40°C/75% RH (accelerated), and potentially refrigerated conditions. Samples are analyzed at predefined time points (0, 3, 6, 9, 12, 18, 24, 36 months) for assay, impurities, dissolution, and physical attributes.

Q: How can one mitigate the risk of polymorphism affecting albendazole tablet performance?

A: Controlling the crystallization process during API synthesis is key. Thorough characterization of the API polymorphic form using techniques like X-ray powder diffraction (XRPD) and DSC is essential. Maintaining consistent manufacturing parameters (temperature, solvent composition) during formulation and granulation can prevent polymorphic transformations. Stability studies should monitor for any changes in polymorphic form over time.

Conclusion

Albendazole tablet manufacturing demands precise control over material properties, process parameters, and environmental conditions to ensure consistent product quality and bioavailability. The low aqueous solubility of albendazole necessitates careful excipient selection and optimized formulation strategies. Adherence to pharmacopeial standards, rigorous quality control testing, and a robust stability program are crucial for maintaining product efficacy and safety.

Future advancements in formulation technologies, such as solid dispersions and nanocrystals, may offer improved bioavailability and reduced dosage requirements. Continuous manufacturing approaches, incorporating real-time process monitoring and control, hold promise for enhancing process efficiency and reducing variability. Ultimately, a comprehensive understanding of the material science, engineering principles, and regulatory requirements is essential for successful albendazole tablet development and commercialization.

Apr . 01, 2024 17:55 Back to list

Albendazole Tablet Price 1 Tablet Manufacturing Analysis